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ABSTRACT 
Little is known about local and systemic biomarkers in relation to synovitis and pain in end-stage 
osteoarthritis (OA) patients. We investigated the associations between the novel extracellular matrix 
biomarker, C1M, and local and systemic interleukin 6 (IL-6) with synovitis and pain. Serum C1M, 
plasma and synovial fluid IL-6 (p-IL-6, sf-IL-6) were measured in 104 end-stage knee OA patients. 
Contrast-enhanced magnetic resonance imaging (MRI) was used to semi-quantitatively assess an 11-point 
synovitis score; pain was assessed by the Western Ontario & McMaster Universities Osteoarthritis 
Index (WOMAC) and the Neuropathic Pain Questionnaire (NPQ). Linear regression was used to investigate 
associations between biomarkers and synovitis, and biomarkers and pain while controlling for age, sex 
and body mass index. We also tested whether associations between biomarkers and pain were confounded 
by synovitis. We found sf-IL-6 was associated with synovitis in the parapatellar subregion (B=0.006; 
95% CI 0.003-0.010), and no association between p-IL-6 and synovitis. We also observed an association 
between C1M and synovitis in the peri-ligamentous subregion (B=0.013; 95% CI 0.003-0.023). Further, 
sf-IL-6, but not p-IL-6, was significantly associated with pain, WOMAC (B=0.022; 95% CI 0.004-0.040) 
and NPQ (B=0.043;95% CI 0.005-0.082). There was no association between C1M and WOMAC pain but we did 
find an association between C1M and NPQ (B=0.229; 95% CI 0.036-0.422). Lastly, synovitis explained 
both biomarker-NPQ associations, but not the biomarker-WOMAC association. These results suggest C1M 
and IL-6 are associated with synovitis and pain, and synovitis is an important confounding variable 
when studying biomarkers and neuropathic features in OA patients. 
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1. INTRODUCTION 
Osteoarthritis (OA) is a common disorder of synovial joints manifested by pain, stiffness, and 
general malfunction of the affected joints. Its pathophysiology is not clearly established, and pain 
is the most disabling symptom [3]. Pain is also the main reason why individuals seek medical care and 
a major factor in loss of joint function [3] leading to surgical intervention, e.g. total knee 
replacement (TKR). 
All knee tissues are affected by OA and almost all are potential sources of pain, except the 
noninnervated articular cartilage. Typical changes in OA-affected joints include progressive 
degeneration ofthe articular cartilage, increased subchondral bone remodelling [14], synovial 
membrane inflammation [31], and meniscal and ligamentous injuries [29]. Magnetic resonance imaging 
(MRI) is a frequently used method for evaluating the contribution of synovitis to OA pathophysiology, 
and different tools are available for quantification of several important characteristics of 
synovitis [13; 16; 19]. Additionally, contrast-enhanced MRI provides more specific assessment of 
synovitis than non-contrast-enhanced MRI [15].Furthermore, the synovial membrane is innervated by 
unmyelinated C-fibres indicating its role as a potential pain generator [34]. C-fibres in joints 
exhibit sensitisation in inflammatory conditions and OA,with decreased thresholds and a stronger 
response to mechanical stimulation [32; 34]. This mechanical hyperalgesia is the main characteristic 
of nociceptive joint pain. There is, however, increasing evidence of a neuropathic component of OA 
pain [10; 11; 40], the type of pain caused by lesions of the somatosensory system [4]. The 
neuropathic-like phenotype in OA has been associated with signs of central sensitisation 
[17; 18] which may augment pain severity [2].  
Biomarkers that can evaluate more subtle, OA-specific changes at a molecular level are needed. 
Biomarkers of the extracellular matrix turnover could help to understand the pathophysiological 
processes that cause pain and joint failure. C1M is a biomarker [27] that has been found to be 
released in an ex vivo model of synovitis [24]. Further, it has been correlated with inflammation in 
rheumatoid arthritis [30; 37; 39], ankylosing spondylitis [36] and OA [38]. However, inflammation 
also involves cytokines which are essential in cell-cell communication and important mediators in the 
aberrant metabolism of joint tissues in OA. The pro-inflammatory cytokine interleukin 6 (IL-6) has 
been found to play an important role in inflammation, arthritis and mechanical hypersensitivity [12; 
21]. Significantly, hyperalgesia induced by IL-6 is persistent and difficult to reverse [6; 7; 33] 
indicating a potential role in chronic pain. However, there are still no reports of a relationship 
between C1M and pain and a possible difference between local and systemic IL-6 in predicting 
synovitis and pain in OA patients. 
Thus, we aimed to explore associations between C1M and IL-6 with synovitis and pain, common 
OA pain and neuropathic features, in patients selected for TKR. Firstly, we hypothesised that the 
extracellular matrix biomarker C1M is associated with synovitis assessed by contrast-enhanced MRI, 
and with both types of pain. Secondly, we hypothesized that local and systemic levels of IL-6 are 
associated with synovitis and pain in these patients. 
 
2. METHODS 
2.1. Study sample 
This exploratory biomarker study (AstraZeneca Study D2285M00029; Clinicaltrials.gov ID: NCT01611441) 
was designed to describe patients with knee OA undergoing TKR surgery using local and systemic 
biomarker levels and MRI. The overall aim of the study was to find a clinically feasible and 
minimally invasive tool for the potential characterisation of OA patients. The study was performed in 
accordance with the ethical principles of the Declaration of Helsinki and according to national and 
international regulations. 
All participants provided their written informed consent. 
This study had explicit inclusion and exclusion criteria. Inclusion criteria were: patient scheduled 
for TKR; man or woman ≥40 years of age; symptomatic OA of the knee for at least 6 months prior to 
enrolment according to clinical and radiological American College of Rheumatology criteria; Western 
Ontario & McMaster Universities Osteoarthritis Index (WOMAC) pain on walking ≥40 mm; calculated 
creatinine clearance >60 mL/min; and willingness and ability to discontinue systemic and topical 
nonsteroid anti-inflammatory analgesics for at least 5 half-lives (wash out period). Exclusion 
criteria included: a current diagnosis of another form of arthritis; arthroscopy performed on the 
target knee within 3 months of enrolment; fibromyalgia or wide spread chronic pain not related to OA; 
use of immunosuppressive medication including steroids or intra-articular hyaluronic acid injections 
within 3 months before enrollment; history of immunodeficiency; history and/or presence of any 
clinically significant disease or disorder (including hepatic, renal, cardiac, metabolic, 
gastrointestinal, pulmonary, haematological, neurological) which has not been stable over the 
previous 3 months, or which may put the patient at risk by participating in the study, influence the 
results or influence the patient’s ability to fully participate; TKR in the contralateral knee; 
significant abnormalities on the clinical assessment of the target knee; use of erythropoietin, 
plasma/blood donation or blood loss >500 mL during the 3 months prior to enrollment; previous 
allogeneic bone marrow transplant; contraindications for MRI; allergy to the contrast agent; or 
participation in another clinical trial. 
The study was conducted in Sweden and Canada at six sites, and was organised into three visits over 
3-20 days depending on the washout period. The first visit included obtaining informed consent at 
enrollment, checking the inclusion and exclusion criteria, and defining the washout period. The 
second visit, one to five days prior to surgery, included clinical examination, MRI investigation, 
and pain assessment using the WOMAC and the Neuropathic Pain Questionnaire (NPQ). The day of surgery 
when blood, plasma, serum, urine, synovial fluid, synovial membrane and cartilage for biomarker 
evaluation were collected was defined as the third visit. Candidates for TKR who completed all three 
visits were included in the study, 104 patients in all. 
2.2. Biomarker measures 
We used two biomarkers as determinants: extracellular matrix biomarker C1M and pro-inflammatory 
cytokine IL-6. C1M is the neo-epitope on position 755-764 of the α1-chain of the type I collagen 
cleaved by matrix metalloproteinases 2, 9 and 13 [27]. Type I collagen is the most abundant collagen 
and its turnover is a part of the normal maintenance of the extracellular matrix [22]. In 
inflammatory conditions, the net loss of type I collagen is elevated due to an increase in levels of 
matrix metalloproteinases. Therefore, C1M reflects inflammatory processes in connective tissues rich 
in type I collagen (bone, tendon, ligament, skin, sclera, cornea and blood vessels). Since C1M is 
destroyed by Cathepsin K, the osteoclast’s main protease, it cannot be released from bone; thus, it 
is a soft connective tissue degradation biomarker. C1M was measured in serum samples using 
competitive enzyme-linked immunosorbent assay (ELISA) at Nordic Bioscience, Herlev, Denmark. Further, 
we measured local levels of IL-6 in synovial fluid (sf-IL-6), and systemic levels in citrate plasma 
samples (p-IL-6) [9] using immunoassays with electrochemiluminescence detection (Meso Scale 
Discovery) at AstraZeneca, Stockholm, Sweden. For statistical analysis, we first inspected for 
outliers, values outside the range [�1 − 1.5 × (�3 − �1), �3 + 1.5 × (�3 − �1)], where Q1 and Q3 are the 
first and third quartile, respectively. We found no outliers among the C1M measures. However, we 
detected five outliers in the p-IL-6 measures (>6.80 pg/mL), and seven outliers in the sf-IL-6 
measures (>594.00 pg/mL) (Supplemental Figure 1). The outliers were excluded from the analysis. They 
could be the result of measurement errors or other medical conditions which we were unable to control 
for, and which could influence the results and the conclusions. 
Biomarkers had positively skewed distributions, meaning that the majority of patients had low levels; 
we used this as a guide for dichotomization. We created a low group – the first tertile of biomarker 
levels (C1M ≤25.23 ng/mL; p-IL-6 ≤1.37 pg/mL; sf-IL-6 ≤30.83 pg/mL), and a high group - the remaining 
two tertiles of biomarker levels (C1M >25.23 ng/mL; p-IL-6 >1.37 pg/mL; sf-IL-6 >30.83 pg/mL). 
Therefore, for statistical purposes, we used both, continuous and dichotomous measures. 
2.3. MRI assessment 
MRI was obtained with a standard knee coil with the subject supine using 1.5T scanners (Signa Excite 
HD 1.5T, GE Healthcare, Milwaukee, Wisconsin; Achieva 1.5T, Philips Medical Systems, Best, the 
Netherlands; or Aera 1.5T, Siemens, Erlangen, Germany). First, intermediate-weighted fast spin-echo 
images with fat suppression (IwFS) in all three planes were acquired (TR=3,600ms, TE=30ms, slice 
thickness=3mm, matrix=512x512, FOV=16). Contrast-enhanced MRI was performed after non-enhanced MRI. 
Renal function was checked for the safety of the subjects. Venous blood samples were collected during 
the first visit and serum creatinine was measured at a central laboratory vendor, Quintiles 
(Quintiles Laboratories Europe, The Alba Campus, Rosebank, Livingston, United Kingdom). Creatinine 
clearance was calculated according to the Cockroft-Gault method: calculated creatinine clearance 
(mL/min)=�140-age(years)�× Weight (kg) 72 ×serum creatinine (mg/dL) [×0.85 (for women)] 
Only patients whose calculated creatinine clearance was above 60 mL/min were selected for pre- and 
postcontrast MRI scanning. Intravenous gadolinium was administered at a dose of 0.2 mL/kg (0.1 
mmol/kg) body weight and followed by a saline flush with 5 mL of saline solution. Injection took 30 
seconds and imaging began 2 minutes later.Sagittal and axial T1-weighted fast spin echo images with 
fat suppression were acquired (TR=385ms, TE=12ms, slice thickness=3mm, matrix=384x384, FOV=16). Non-
enhanced and contrast-enhanced sequences were anonymised and centrally read by two experienced 
musculoskeletal radiologists (AG, MDC). The MRI osteoarthritis knee score (MOAKS) was used to semi-
quantitatively score intercondylar Hoffa-synovitis and whole knee effusion-synovitis [19]. 
Hoffasynovitis, on sagittal IwFS images, presents ill-defined high-signal intensity of Hoffa’s fat 
pad at the intercondylar region on fluid-sensitive sequences [8]. Effusion-synovitis, on axial IwFS 
images, shows a combination of joint effusion and synovial thickening on fluid-sensitive sequences 
depending on the degree of joint cavity swollenness [8]. For volumetric evaluation of total synovial 
volume in mm³ [13], the synovium was manually segmented using all sagittal T1wFS images, on a slice-
by-slice basis by one reader (AFH, non-author) under the supervision and in consensus with an 
experienced musculoskeletalradiologist (AG). Segmentation was done using the 3D software ITK-snap 
(Penn Imaging Computing and Science Laboratory) [8]. Lastly, synovial thickness, measured in 
millimetres on contrast-enhanced MRI (axial and sagittal T1wFS images), was evaluated semi-
quantitatively using a scoring system described by Guermazi et al [16] at 11 anatomical regions with 
subscores (parapatellar, peri-ligamentous and perimeniscal). We used continuous measures (11-point 
synovitis sum score 0-22; parapatellar subscore 0-10; peri-ligamentous subscore 0-4; peri-meniscal 
subscore 0-4) and a dichotomized 11-point synovitis scores. Since no one patient had a low synovitis 
score, our groups were: mild/moderate (11-point synovitis sum score 5-12; 34.6% patients) and severe 
(11-point synovitis sum score > 12; 65.4% patients) synovitis [16].  
2.4. Pain assessment 
We used two different questionnaires to assess osteoarthritic pain: WOMAC 48 hours recall, and the 
NPQ. The WOMAC consists of three subscales: pain, stiffness, and functional limitations; only the 
pain scale was used in this study. We used a visual analogue scale version of the WOMAC (VA3.1) [5], 
meaning that five WOMAC questions were scored on a 100 mm scale, starting from 0 mm (no pain at all) 
to 100 mm (extreme pain). The patients filled in the WOMAC on two occasions: at the first visit when 
a response of ≥40 mm to 'walking on a flat surface’ was used as inclusion criteria, and at the 
second visit before imaging. Similarly, on the same two occasions patients filled in the NPQ, a self-
administered questionnaire with 12 items representing various aspects or qualities of pain [25]. This 
instrument also uses a 100-point scale, where 0 represents no pain and 100 is the worst pain 
imaginable. In the present study, for the purpose of statistical analysis, only the questionnaires 
from the second visit were used. Further, for statistical purposes, scales of both instruments were 
transformed by dividing the sum scores by 10; this resulted in a transformed WOMAC pain score of 0-50 
and a transformed NPQ score of 0-120.Also, we computed dichotomous pain variables. We dichotomized 
WOMAC pain similarly to our first outcome, the 11-point synovitis score, creating the mild/moderate 
group – first two tertiles of the WOMAC pain (transformed score ≤32.60 mm), and the severe group – 
the last tertile of the continuous measure (transformed score >32.60 mm). The NPQ is a screening tool 
that aids in differentiating neuropathic from non-neuropathic pain, and provides a calculation of the 
discriminant score for two groups; we computed these two groups for our analyses as well (neuropathic 
pain group 46.1%, non-neuropathic pain group 53.9% of patients) [25]. Defined in this way, the 
neuropathic pain group is likely to have neuropathic features, although that does not necessarily 
mean a diagnosed condition that requires further examinations. 
2.5. Statistical analysis 
We described the study sample using measures for location and measures of spread for Gaussian and 
non-Gaussian distribution. Further, Spearman’s correlation analysis was performed to show 
relationships between the variables of interest. To examine the association between continuous 
biomarker levels C1M and IL-6 with synovitis we used linear regression analysis. The analyses were 
performed step by step presenting the unadjusted results (Model 1), and results adjusted for age, 
gender, and body mass index (BMI) (Model 2). Similarly, to examine the association between biomarkers 
and pain we used the same models in the linear regression analyses. Additionally, to examine the 
possible confounding effect of synovitis in these biomarker-pain relationships, we fitted an 
additional model adjusted for the 11-point synovitis score (Model 3). Furthermore, we used 
dichotomous variables and performed logistic regression analysis. Since this is an additional 
analysis we reported only the adjusted results: Model 2 was used in the synovitis analyses, and 
Model 3 was used in the pain analyses. Interpretation of the findings was primarily based on the 
results from the main analyses; additional analyses were intended to complement the main analyses and 
to show the results of probability function in addition to a linear function. This was done because 
the biomarkers, predictors in all analyses, are commonly used as both, continuous and dichotomous 
measures. This approach should allow comparison with results from a wide range of similar studies. We 
did not aim to compare biomarkers and synovitis as predictors of pain; synovitis was used as an 
outcome in the first group analyses, and as a confounding variable in the second group analyses when 
the association biomarker-pain was investigated. We reported beta coefficients (B) in linear 
regression analyses, odds ratios (OR) in logistic regression analyses, their 95% confidence interval 
(CI) and p-value. Betas represent an increase or decrease in Synovitis score (0-22), WOMAC pain score 
(0-50) or NPQ score (0-120) per unit of increase of C1M (ng/mL) or IL-6 (pg/mL). OR denotes the odds 
of having severe synovitis, severe pain measured by WOMAC, or neuropathic pain according to NPQ when 
having a high level of C1M or IL-6 compared to the low level of these biomarkers. Type I error level 
was set at 5% (p<0.050). No imputation was done for missing values, so the number of participants 
included in each analysis varies. All statistical analyses were performed using Statistical Package 
for the Social Sciences (SPSS), 23.0 (IBM, Armonk, New York, USA). 
  
3. RESULTS 
3.1. Descriptive Statistics 
The study sample characteristics are shown in Table 1. Patients were 67 years old on average, 61.5% 
were women and their mean BMI was around 30 kg/m2. In this sample of TKR patients, all three 
biomarker levels were positively skewed, the median C1M level was 31.44 ng/mL (interquartile range 
(IQR)=21.86-45.93), the median p-IL-6 was 1.71 pg/mL (IQR=1.09-2.54), and median sf-IL-6 was 71.05 
pg/mL (IQR=21.35-150.00). Further, we assessed two outcome groups, synovitis and pain. Among MRI 
measures of synovitis, the main measure was the 11-point synovitis score; it was normally distributed 
(Kolmogorov-Smirnov statistics (K-S)=0.086df=104, p=0.055) with a mean value 14.27 (standard deviation 
(SD)=3.67). We also took into account the parapatellar, peri-ligamentous and peri-meniscal synovitis 
subscores of this full score (Table 1). In this study sample, synovial volume (K-S=0.072df=104, 
p=0.200) was on average 56.01 mL (SD=17.14). The MOAKS measures of synovitis, intercondylar Hoffa-
synovitis, and whole knee effusion synovitis are semi-quantitative scores with values 0 to 3. Whole 
knee effusion-synovitis was prevalent with 74.0% of patients having grades 2 or 3, while Hoffa-
synovitis was less prevalent with 64.4% of patients having grades 0 or 1. The second group of 
outcomes were pain assessments; WOMAC pain (K-S=0.039df=104,p=0.200) with mean 28.75 (SD=9.18) and NPQ 
(K-S= 0.086df=104, p=0.057) with mean 40.83 (SD=19.97). We performed Spearman’s correlations between 
variables included in this study (Table 2). We found a statistically significant positive correlation 
between C1M and p-IL-6 (rs=0.27, p=0.017), but not between C1M and sf-IL-6 (rs=0.08, p=0.502). C1M 
also positively correlated with the 11-point synovitis score (rs=0.28, p=0.006) and with both pain 
assessments, WOMAC (rs=0.20, p=0.049) and NPQ (rs=0.22, p=0.027). Interestingly, we found that p-IL-6 
positively correlated with biomarkers levels, with C1M and synovial fluid IL-6 (rs=0.28, p=0.022), 
but not with any synovitis or pain assessment. Additionally, sf-IL-6 correlated positively with the 
11-point synovitis score (rs=0.28, p=0.012) and synovial volume (rs=0.39, p<0.001), but not with the 
pain assessments. As expected, synovitis measures correlated positively and significantly with each 
other. Of these synovitis measures only the11-point synovitis score correlated positively with pain 
measures, WOMAC (rs=0.19, p=0.048) and NPQ (rs=0.25, p=0.011). Furthermore, in this sample, we found 
that pain assessments WOMAC and NPQ were positively and strongly correlated (rs=0.62, p<0.001). 
 
3.2. Association between Biomarkers and Synovitis 
We tested the association between C1M serum levels and the 11-point synovitis score using linear 
regression analysis and found a trend toward significance (Model 2: B=0.033; 95% CI -0.006, 0.072; 
p=0.096). We tested C1M in relation to synovitis subscores to check for possible subscore-driven 
effects. In this case, we found that C1M was positively associated with synovitis in the peri-
ligamentous subregion (Figure 1) when confounding variables were taken into account (B=0.012; 95% CI 
0.002, 0.022; p=0.018) (Table 3). 
On the other hand, we did not find any association between p-IL-6 measures and synovitis measures, 
(Table 3). However, we did find an association between sf-IL-6 levels and the 11-point synovitis 
score (Model 2: B=0.009; 95% CI 0.002, 0.016; p=0.018), and subscore-specific analyses showed that 
this association was driven by synovitis in the parapatellar subregion (Figure 1) (adjusted B=0.006; 
95% CI 0.002, 0.009; p=0.003) (Table 3). In addition, we found an association between sf-IL-6 and 
synovial volume in the unadjusted model (B=0.038; 95% CI 0.004, 0.072; p=0.029) and also after 
controlling for confounding variables (B=0.040; 95% CI 0.004, 0.076; p=0.030). 
 
3.3. Association between Biomarkers and Pain 
We examined the association between C1M serum levels and WOMAC pain using linear regression analysis 
and found a statistically significant association in the unadjusted model (B=0.101; 95% CI 0.006, 
0.196; p=0.038). However, when confounding effects of age, gender and BMI were taken into account the 
association was not statistically significant (B=0.075; 95% CI -0.014, 0.164; p=0.096). Further, we 
also tested the association between C1M and NPQ and found a positive association in the adjusted 
model (B=0.229; 95% CI 0.036, 0.422; p=0.020). When we performed an additional Model 3, we found that 
the synovitis sum score explained the observed association (B=0.190; 95% CI -0.001, 0.380; p=0.051) 
(Table 4). Further, we studied the association between IL-6 and pain. We found no association between 
p-IL-6 and WOMAC pain, but there was a weak association between p-IL-6 and NPQ which was explained 
after controlling for the confounding effects of age, sex, and BMI (B=4.029, 95% CI -0.318, 8.376; 
p=0.069). In contrast, the association between sf-IL-6 and WOMAC pain was not statistically 
significant until confounding variables were taken into account (B=0.022, 95% CI 0.004, 0.040; 
p=0.016). This association between sf-IL-6 and WOMAC pain remained statistically significant even 
after correcting for the synovitis score (B=0.020, 95% CI 0.001, 0.038; p=0.038) (Table4). Similarly, 
the association between sf-IL-6 and NPQ was statistically significant only when confounding variables 
were taken into account (B=0.043, 95% CI 0.005, 0.082; p=0.026), but this association was explained 
by the synovitis score (B=0.031, 95% CI -0.007, 0.069; p=0.112). 
 
3.4. Additional Analyses  
To complement the main analyses, we used logistic regression to test the association between 
dichotomous biomarkers and dichotomous synovitis level. We found that patients with a high C1M level 
and a high sf-IL-6 level had the increased odds (OR=3.60; 95% CI 1.37, 9.46; p=0.009; and OR=3.88; 
95% CI 1.30, 11.60; p=0.015, respectively) of having severe synovitis when compared to the referent 
low levels. We found no association between dichotomous measures of p-IL-6 and synovitis (Table 5). 
We used the same dichotomous approach for studying pain. We found no difference in WOMACmeasured pain 
between high and low levels of any of the biomarkers. However, we found that TKR candidates with high 
C1M levels had the increased odds of having neuropathic pain according to the NPQ (OR=3.52; 95% CI 
1.26, 9.80; p=0.016) even when synovitis was included as a confounding variable. Thus, the 
discrepancy between the main and the additional analysis found in the C1M-NPQ relationship favoured 
the additional analysis. We found no association between dichotomous IL-6, local or systemic, and NPQ 
(Table 5). Discriminative properties of dichotomous biomarkers in a stacked bar graph style with 
percent showing outcome values within the low or high biomarker level are shown in Supplemental 
Figure 2.  
 
4. DISCUSSION 
We found that, in OA patients scheduled for TKR, the extracellular matrix biomarker C1M was 
associated with synovitis in the peri-ligamentous subregion, and with neuropathic features. However, 
this association was no longer significant when synovitis was introduced as a confounding variable 
into the model of C1M and neuropathic features. Further, we found that local, but not systemic 
measures of IL-6 were associated with synovitis in the parapatellar subregion, and with pain as 
assessed by both WOMAC and NPQ. Similarly, as with C1M, the association between synovial fluid IL-6 
and neuropathic features was explained by synovitis (Figure2).  
This cross-sectional study suggests that end-stage OA is local, low-grade inflammation associated 
with neuropathic symptoms. Synovitis is the main inflammatory characteristic of OA and we found in 
this study sample that all patients had synovitis to some extent, with 65.4% having severe synovitis. 
The presence of inflammation in patients selected for TKR is in agreement with previous reports 
describing end-stage OA patients [41]. 
This study investigated the important difference between local and systemic IL-6 levels in predicting 
synovitis assessed by contrast-enhanced MRI, unlike previous research which has been mainly focused 
on IL-6 in relation to radiographic OA. We only observed the relationship between local, synovial 
fluid IL-6 levels and synovitis. Interestingly, local IL-6 was additionally associated with synovial 
fluid volume that determines joint swelling confirming the importance of this cytokine in joint 
inflammation. Conversely, no association between plasma IL-6 and synovitis was observed. Findings on 
the contribution of IL-6 to OA pathophysiology are mixed: some studies showed a significant 
predictive function [28], while others reported no association between serum IL-6 and radiographic 
OA, and a negative relationship between local IL-6 levels and OA progression [20]. Other authors also 
reported no findings between systemic IL-6 levels and histological synovitis score in end-stage OA 
patients [41]. Systemic concentrations of IL-6 are measured in serum or plasma, yet IL-6 is the most 
stable in citrate plasma samples [9]. However, serum and plasma concentrations usually correlate 
highly, so the findings for systemic IL-6 measures should be comparable and provide similar 
conclusions. The lack of findings between plasma IL-6 measures and synovitis could be due to the 
altered properties of the synovium affecting the permeability of IL-6 between the local and the 
systemic compartments or more likely, contribution from other tissues to the systemic level. 
Furthermore, we investigated the extracellular matrix biomarker C1M in relation to synovitis. The 
synovial membrane is a source of matrix metalloproteinases which generate this biomarker [31] and C1M 
has been found to be released from an ex vivo model of inflamed synovium [24]. These synovial biopsies 
are isolated from patients undergoing TKR, and this clinical study evaluates biomarkers and MRI 
measures in a comparable group of patients allowing comparison to different study reports and 
findings that confirm each other. Interestingly, a systemic measure of C1M provides a comparable 
amount of information as a local IL-6 measure when investigating synovitis. However, C1M and IL-6 
were related to synovitis at different anatomical regions. The 11-point synovitis instrument scores 
inflammation in those parts of the synovium adjacent to bone (patella), soft connective tissue 
(ligament) and a fibrocartilaginous structure (meniscus). It has been found that IL-6 plays an 
important role in bone metabolism [26] and C1M is related to soft connective tissue, so our findings 
were expected. However, the peri-ligamentous subregion accounts for a small part of the sum score 
providing a possible explanation for why only a trend toward significance between C1M and the 
synovitis sum score was found. Lack of findings in the peri-meniscal subregion offers confirmation 
since none of the biomarkers would be expected to reflect the fibrocartilaginous compartment. 
The most pronounced symptom and the important criterion for TKR is severe pain. To better describe 
and understand pain in end-stage OA, we investigated two different dimensions of pain, common 
WOMAC pain and a neuropathic component. WOMAC is the most widely used pain instrument in the OA field 
and defines pain while walking, resting and standing; we also used NPQ, a validated instrument [25] 
for assessing neuropathic symptoms. 
Here, we report that extracellular matrix degradation is associated with neuropathic features in 
OA, and that there is a difference between synovial fluid and plasma IL-6 levels and their 
associations with these two components of OA pain. Measurements in synovial fluid, expected to 
reflect local joint events, were significantly associated with both pain dimensions, while systemic 
IL-6 levels were not associated with pain. Still, systemic C1M can substitute for the more invasive 
measurement of local IL-6 in describing neuropathic features. Showing that synovitis is a confounding 
variable in the biomarker-NPQ associations indicates that levels of C1M in serum and IL-6 in synovial 
fluid that predict pain depend on synovitis. To our knowledge, these three findings are novel in the 
OA field. Importantly, local IL-6 is associated with WOMAC pain independently of synovitis. This 
could mean that IL-6 describes OA changes in other knee compartments associated with walking or 
standing captured by the WOMAC pain scale. The lack of association between C1M and WOMAC pain further 
favours the possibility that inflammation and soft connective tissue degradation are more 
specifically associated with neuropathic symptoms. It has been reported that in early OA but not in 
advanced OA [35] serum IL-6 is associated with pain as assessed by the Japanese Knee Osteoarthritis 
Measure, which is comparable to WOMAC [1]. Our study adds that there is no association in end-stage 
OA. We can speculate that if inflammation is a driver of OA, then in the early stage IL-6 
concentrations peak in synovial fluid and consequently the contribution of joint IL-6 to the total 
circulation level is more significant; thus, the systemic IL-6 measure could be used as a determinant 
of pain. 
As the disease becomes chronic, IL-6 levels may decrease in synovial fluid thereby affecting systemic 
IL-6 levels; the systemic level accounts for IL-6 from other tissues and it describes joint pain to a 
smaller extent, often not significantly. This also suggests that in prospective OA studies, a 
quadratic, rather than a linear relationship between systemic IL-6 and pain could be investigated. 
This study was designed with a number of important strengths. It used a homogeneous sample, allowed 
for a wash-out period to eliminate medication effects, it measured both local and systemic IL-6 
levels, sought to investigate a novel biomarker C1M, assessed synovitis using contrast-enhanced MRI 
and evaluated two dimensions of pain. It does, of course, have limitations. First, this is a cross-
sectional study; we described the study sample at a single time point and it provides no insight into 
associations regarding progression or prognosis. As a result, our conclusions should be restricted to 
describing end-stage OA patients. Second, having a homogeneous sample reduces inter-subject 
variability, which is an advantage in many ways, but a drawback in terms of external validity. Third, 
our sample size, 104, is rather moderate and small effects may not be detectable in a group of this 
size. Fourth, pressure pain thresholds could complement pain assessment. Further, OA in other joints 
was not assessed and we could not control for this in the analyses that included the systemic 
biomarker assessments. Lastly, we accounted for the influence of the most common confounding 
variables in the statistical analyses, but this study like other observational studies cannot exclude 
residual confounding which could be related to both, determinant and outcome. 
In spite of some inevitable shortcomings, our study provides interesting findings that should be 
further investigated in well-designed studies. Although synovitis is an important descriptor of end-
stage OA, what triggers the onset and drives disease progression remains to be determined. Further 
research is needed to understand the relationship between synovitis and neuropathic features in OA. 
It might be expected that subjects scheduled for TKR would provide a homogenous sample to study, 
however, it is more likely that different phenotypes drive the course of the disease, and defining 
these could improve targeted pharmacological research and eventually treatment. Biomarkers which 
reflect extracellular matrix remodelling have a potential to define different OA phenotypes, and 
could provide key insights to guide research on identifying mechanisms suitable for pharmacological 
intervention [23].  
In conclusion, our study suggests that C1M and local IL-6, but not systemic IL-6 levels, are 
associated with synovitis and pain and that these biomarkers are not independently associated with 
neuropathic features when synovitis is taken into account. This suggests an important confounding 
effect of synovitis in the relationships of biomarkers and neuropathic features in OA patients. 
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Figure 1 Synovitis seen on fat-suppressed contrast-enhanced MRI; a) axial view – mild medial (arrow) 
and moderate lateral (small arrows) parapatellar synovitis; b) sagittal view – moderate suprapatellar 
(arrow) and severe synovitis posterior to posterior cruciate ligament (small arrows). 
 
 
 
Figure 2 Schematic presentation of the findings from this study; a) serum C1M and synovial fluid IL-6 
(sf-IL-6) are associated with synovitis and neuropathic features (NPQ), and synovitis is a 
confounding variable in the relationships biomarkers-NPQ; the latter tells that biomarker levels that 
predict NPQ depend on the synovitis score; b) plasma IL-6 (p-IL-6) is not associated with synovitis 
and NPQ; c) sf-IL-6 is associated with WOMAC pain, and synovitis is not a confounding variable in the 
relationship biomarker-WOMAC pain; the latter tells that biomarker predicts WOMAC pain independently 
of synovitis; d) C1M and p-IL-6 are not associated with WOMAC pain. 
 
  
Supplemental Figure 1 Distributions of biomarkers are shown on histogram (left) and boxplot (right) 
graphs; stars indicate outliers, and circles indicate extreme values that are not outliers; a) C1M; 
b) plasma IL-6 – original data; c) plasma IL-6 – after excluding 4+1 outliers in two steps; d) 
synovial fluid IL-6 – original data; e) synovial fluid IL-6 – after excluding 5+2 outliers in two 
steps. 
 
 
Supplemental Figure 2 Dichotomization of the outcome variables and discrimination between these values 
by dichotomous biomarkers. Low level is the first tertile of a biomarker distribution; high level is 
the second and third tertiles. Histogram shows distribution and the red line indicates the cut-off 
for dichotomization; in the stacked bar graphs, the stacks represent the percent of the outcome 
values within low or high biomarker level; A light colour indicates mild/moderate synovitis or WOMAC 
pain, or nonneuropathic pain according to Neuropathic Pain Questionnaire (NPQ), and a dark colour 
indicates severe synovitis or WOMAC pain, or neuropathic pain according to NPQ. Biomarker sensitivity 
is shown by a dark coloured stack in a high biomarker bar while biomarker specificity is indicated by 
a light coloured stack in a low biomarker bar; the larger the two stacks the better the sensitivity 
and specificity of the biomarker; a) distribution of the 11-point synovitis sum score and 
dichotomization to mild/moderate and severe synovitis; b-d) discrimination between mild/moderate and 
severe synovitis by low and high serum C1M, plasma IL-6 and synovial fluid IL-6 levels; e) 
distribution of the WOMAC pain score and dichotomization to mild/moderate and severe WOMAC pain; f-h) 
discrimination between mild/moderate and severe WOMAC pain by low and high serum C1M, plasma IL-6 and 
synovial fluid IL-6 levels; i) distribution of the total discriminant function score of the NPQ that 
is used for dichotomization to non-neuropathic and neuropathic pain according to the NPQ; note: this 
score is derived from the NPQ, this is not a distribution of the NPQ; j-l) discrimination between 
non-neuropathic and neuropathic pain according to NPQ by low and high serum C1M, plasma IL-6 and 
synovial fluid IL-6 levels. In all cases, serum C1M has the highest sensitivity and specificity 
compared to plasma and synovial fluid IL-6, yet all three biomarkers have quite low specificity. 
